Results 211 to 220 of about 89,537 (296)

Characterization of Second-Line Therapy After First JAK Inhibitor Use: Results From the CorEvitas Rheumatoid Arthritis Registry. [PDF]

ACR Open Rheumatol
Baker JF, Mizelle KV, Saikali W, Moore PC, Kang HJ, Gruben D, Shelbaya A, Stockert L, O'Brien J.   +8 more
europepmc   +1 more source

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

Molecular Oncology, EarlyView.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober, Leire Moreno‐Cugnon, Laura Martínez‐Pérez, Amaia Ercilla, Amaia Zabala‐Letona, Adrián Vicente‐Barrueco, Maider Fagoaga‐Eugui, Saioa Garcia‐Longarte, Blanca Calle‐Ciborro, Encarnación Pérez‐Andrés, Onintza Carlevaris, Sara Pozo, Isabel Mendizabal, Ugo Mayor, Arkaitz Carracedo, Violaine Sée, Edurne Berra   +16 more
wiley   +1 more source

Deep Immunophenotyping Reveals a Resilient Tph-ABC Axis in Difficult-to-treat Rheumatoid Arthritis: A Case Report of JAK Inhibitor Failure Complicated by Herpes Zoster and Thrombosis. [PDF]

In Vivo
Wu CL, Lu JW, Ho YJ, Lui SW, Hsieh TY, Jheng WL, Liu FC.   +6 more
europepmc   +1 more source

Bullous Central Serous Chorioretinopathy Associated With JAK Inhibitor Use. [PDF]

J Vitreoretin Dis
Apel W, Li Y.
europepmc   +1 more source

Finding novel vulnerabilities of hypomorphic BRCA1 alleles

Molecular Oncology, EarlyView.
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder, Klaas de Lint, Hồ Mỹ Phúc Võ, Mariana M. Góis, Rosalie A. Kampen, Marta San Martin Alonso, Ilse Nootenboom, Veronica Garzero, Tiemen J. Wendel, Rob M. F. Wolthuis, Sylvie M. Noordermeer   +10 more
wiley   +1 more source

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

Molecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi, Stavros Makrodimitris, Sandra van Wilpe, Iris te Paske, Vanja de Weerd, Corine M. Beaufort, Hans M. Westgeest, Jens Voortman, Maureen J. B. Aarts, Maud Rijnders, Astrid A. M. van der Veldt, Ronald de Wit, Niven Mehra, Saskia M. Wilting, Debbie G. J. Robbrecht   +14 more
wiley   +1 more source

Infectious retinitis associated with JAK inhibitors: the ongoing duality of JAK inhibitors

International Journal of Retina and Vitreous
Pulido, Jose S., Mano, Fukutaro, Casella, Marcello, Ishida, Susumu   +3 more
openaire   +2 more sources

Pharmacokinetic Monitoring of JAK Inhibitor and Tacrolimus for Safe and Effective Management of Graft-Versus-Host Disease After Pediatric Liver Transplantation. [PDF]

Pediatr Transplant
Sawada K, Khandelwal P, Davies SM, Crooker A, Mizuno T, Asai A.   +5 more
europepmc   +1 more source

MITF maintains genome stability in nonmelanocyte lineages

Molecular Oncology, EarlyView.
MITF is essential for melanocyte survival and acts as an oncogene in 10%–20% of melanomas. We show that MITF depletion causes genome instability in nonmelanocytic cells, leading to LATS2‐mediated P53 activation, cell cycle arrest, and apoptosis. This study highlights the role of MITF as a genome maintenance factor beyond the melanocyte lineage. Created
Drifa H. Gudmundsdottir, Adrián López García de Lomana, Thejus B. Venkatesh, Kritika Kirty, Snaevar Sigurdsson, Linda Vidarsdottir, Ramile Dilshat, Erla Sveinbjornsdottir, Snaedis Ragnarsdottir, Daniel H Magnusson, Maria R. Bustos, Eirikur Steingrimsson, Thorkell Gudjonsson, Stefan Sigurdsson   +13 more
wiley   +1 more source

Targeting interferon responses in juvenile dermatomyositis: Siglec-1 as an in vitro biomarker for JAK inhibitor efficacy. [PDF]

Rheumatology (Oxford)
Veldkamp SR, Reugebrink M, Evers SW, Moreau TRJ, Bondet V, Armbrust W, van den Berg JM, Hissink Muller PCE, Kamphuis S, Schatorjé E, Delemarre EM, van der Kooi AJ, Bader-Meunier B, Duffy D, Rodero MP, Raaphorst J, van Royen-Kerkhof A, Jansen MHA, van Wijk F.   +18 more
europepmc   +1 more source